Xcout IntelArcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics is a biotechnology company focused on medical dermatology innovation. The company is publicly traded and dedicated to delivering meaningful treatments in the dermatology field.
Subscribe to see Arcutis Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Arcutis Biotherapeutics, Inc. at a glance
Arcutis Biotherapeutics, Inc. is a biotechnology company headquartered in Westlake Village, United States. It is publicly listed (ARQT) with a market capitalisation of $3.6B. Xcout tracks 46 named people at Arcutis Biotherapeutics, Inc., including Todd Franklin Watanabe (President, Chief Executive Officer & Director).
Arcutis Biotherapeutics, Inc. leadership
- Todd Franklin WatanabePresident, Chief Executive Officer & Director
- Frank WatanabePresident and CEO
- Latha VairavanSenior Vice President & Chief Financial Officer
- L. Todd EdwardsExecutive Vice President & Chief Commercial Officer
- Patrick E. BurnettExecutive Vice President & Chief Medical Officer
- Masaru MatsudaExecutive VP, Chief Legal Officer & Corporate Secretary
40 more named people on record for Arcutis Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
Arcutis Biotherapeutics, Inc. competitors
A few of Arcutis Biotherapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Aldena Therapeutics is a biotechnology company focused on transforming dermatology through novel siRNA-based treatments for skin conditions.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Get Arcutis Biotherapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Arcutis Biotherapeutics, Inc. in Xcout Intel
- 46 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access